Personalized Stem Cells Licenses its Allogeneic Stem Cell Platform to Sorrento
shot by IP News Shots / 10:42 am on 15 October, 2020
An exclusive licensing agreement has been signed between Personalized Stem Cells Inc. (PSC) and Sorrento Therapeutics Inc. for the former’s allogeneic stem cell platform including COVID-19 therapy candidate. The agreement will allow Sorrento to speed up the COVID-19 development program with potential global reach. As per the terms of the agreement PSC will receive an upfront payment of $3.5 million along with other milestone and royalty payments.
Industry: Biotechnology | Type of IP: Deals - Licensing